Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China

Abstract Background There is limited data on the clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in a real‐world setting for Chinese patients with advanced ALK+ NSCLC. Methods The medical records of patients who received sequ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zihua Zou, Xuezhi Hao, Cuiying Zhang, Haojing Li, Guilan Dong, Yumei Peng, Kewei Ma, Ye Guo, Li Shan, Yan Zhang, Li Liang, Yangchun Gu, Puyuan Xing, Junling Li
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2022-01-01
Colecção:Thoracic Cancer
Assuntos:
Alectinib
ALK+ NSCLC
Crizotinib
Acesso em linha:https://doi.org/10.1111/1759-7714.14232
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados